State of Michigan Retirement System Increases Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

State of Michigan Retirement System lifted its position in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 1.9% in the first quarter, Holdings Channel reports. The firm owned 26,266 shares of the life sciences company’s stock after buying an additional 500 shares during the period. State of Michigan Retirement System’s holdings in Integra LifeSciences were worth $1,815,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Janus Henderson Group PLC boosted its holdings in shares of Integra LifeSciences by 14.1% in the fourth quarter. Janus Henderson Group PLC now owns 4,622,163 shares of the life sciences company’s stock valued at $300,071,000 after purchasing an additional 572,291 shares during the period. Cooke & Bieler LP raised its stake in Integra LifeSciences by 9.9% in the fourth quarter. Cooke & Bieler LP now owns 2,710,733 shares of the life sciences company’s stock worth $175,981,000 after buying an additional 244,503 shares in the last quarter. Eaton Vance Management raised its stake in Integra LifeSciences by 46.8% in the fourth quarter. Eaton Vance Management now owns 2,487,433 shares of the life sciences company’s stock worth $161,484,000 after buying an additional 792,588 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Integra LifeSciences by 2.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 904,565 shares of the life sciences company’s stock worth $58,725,000 after buying an additional 22,722 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in Integra LifeSciences by 11.5% in the fourth quarter. Wells Fargo & Company MN now owns 850,233 shares of the life sciences company’s stock worth $55,197,000 after buying an additional 87,492 shares in the last quarter. Hedge funds and other institutional investors own 85.71% of the company’s stock.

In other Integra LifeSciences news, EVP Lisa Evoli sold 5,335 shares of the company’s stock in a transaction on Monday, May 10th. The shares were sold at an average price of $75.00, for a total value of $400,125.00. Following the sale, the executive vice president now directly owns 10,415 shares of the company’s stock, valued at $781,125. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Eric Schwartz sold 4,212 shares of the company’s stock in a transaction on Tuesday, March 2nd. The shares were sold at an average price of $69.10, for a total transaction of $291,049.20. Over the last three months, insiders sold 1,091,687 shares of company stock worth $74,779,686. 4.30% of the stock is owned by insiders.

NASDAQ IART opened at $70.79 on Monday. The company has a debt-to-equity ratio of 1.08, a current ratio of 4.52 and a quick ratio of 3.31. The stock’s fifty day moving average price is $71.55 and its 200 day moving average price is $64.76. Integra LifeSciences Holdings Co. has a 1 year low of $42.12 and a 1 year high of $77.40. The company has a market cap of $5.99 billion, a price-to-earnings ratio of 105.66, a PEG ratio of 1.97 and a beta of 1.26.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Tuesday, April 27th. The life sciences company reported $0.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.12. Integra LifeSciences had a return on equity of 14.26% and a net margin of 4.10%. The firm had revenue of $360.10 million for the quarter, compared to the consensus estimate of $349.78 million. During the same period in the prior year, the firm earned $0.48 EPS. The firm’s revenue was up 1.6% on a year-over-year basis. Research analysts expect that Integra LifeSciences Holdings Co. will post 2.36 earnings per share for the current year.

A number of equities analysts recently commented on IART shares. Oppenheimer boosted their price objective on shares of Integra LifeSciences from $79.00 to $88.00 and gave the stock an “outperform” rating in a research note on Thursday, April 29th. JMP Securities boosted their price objective on shares of Integra LifeSciences from $65.00 to $80.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 27th. Citigroup boosted their price objective on shares of Integra LifeSciences from $70.00 to $78.00 in a research note on Thursday, April 29th. BTIG Research boosted their price objective on shares of Integra LifeSciences from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Tuesday, January 19th. Finally, Piper Sandler upped their price target on Integra LifeSciences from $47.00 to $65.00 and gave the stock a “neutral” rating in a research report on Friday, January 29th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $71.36.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. It operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

See Also: Tariff

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.